Supplement and nutraceutical brand due diligence

Due diligence on a supplement and nutraceutical brand is built around one central question: does every product actually being sold right now carry a valid, current Health Canada licence, and will the contract manufacturer and the marketing claims behind it survive scrutiny once you own the business. Because the regulatory file here is as much a part of the asset as the formulation or the customer base, verification has to be done SKU by SKU rather than at the brand level, and it has to be done before the LOI’s exclusivity period expires rather than left as a closing-day formality.

Build a SKU-by-SKU licence register — do not rely on the seller’s summary

Pull the actual current storefront listing and match every product, flavour and format against its Natural Product Number individually, rather than accepting a seller-provided summary that may not have been updated as new line extensions launched. Cross-check the licence status directly rather than relying on a screenshot or a claim it was confirmed previously, since a licence that lapsed or an application that stalled between the seller’s last check and today is exactly the kind of gap this exercise exists to catch.

Confirm the contract manufacturer’s site licence independently

Verify the current status of the site licence for whichever facility manufactures, packages, labels or imports the product, rather than relying on the seller’s assurance that the manufacturer is in good standing, because a facility with a suspended or under-review site licence can halt production regardless of how sound the brand’s own licensing is. If the formulation depends on a single manufacturer with no qualified backup, treat that concentration itself as a finding worth pricing into the deal, not just a fact to note in passing.

Confirm trademarks and formulation documentation actually transfer

Beyond the regulatory file, confirm the brand’s trademarks are registered and assignable, and that the actual formulation and recipe documentation — not just a marketing summary — is being provided in a form the buyer can hand to a new or backup manufacturer if needed. A brand that owns its formulation only in the sense that a single contract manufacturer happens to know it, with no written documentation the business itself controls, is a materially weaker asset than one that holds usable, transferable technical documentation independent of any one supplier relationship.

Check label and marketing claims against the licence, not against what sounds reasonable

Compare every health or performance claim appearing on the label, the website and any advertising directly against what the product’s Natural Product Number authorization actually permits it to say, since the Competition Act’s misleading-representations provisions apply to marketing independently of whatever the licence covers. A claim that sounds plausible or common across the category is not the same as a claim the specific licence actually supports, and the gap between the two is a common, underappreciated finding in this sub-sector.

Reconcile the inventory expiry schedule against the reported inventory value

Request the full inventory listing broken out by SKU and expiry or best-before date, and compare it against how the inventory has been valued on the balance sheet, since product close to its date needs to be written down rather than counted at cost. A reported inventory figure that has not been adjusted for a meaningful batch of near-expiry stock overstates what the buyer is actually acquiring, and this is one of the more common gaps between the seller’s numbers and the underlying reality.

Check GST/HST filings and any CBSA import records against the licence file

Where the brand imports finished product or raw ingredients, request CBSA import and duty records and confirm they reconcile against what the business has actually declared, since this obligation sits separately from and alongside Health Canada’s product-licensing regime rather than being covered by it. Reconcile GST/HST remittance history against actual online sales volume as a routine cross-check, the same way you would for any e-commerce business, since a licensing file that is in perfect order says nothing about whether the tax and import side of the business has kept pace.

What a finding actually means once you have it

Not every gap found during diligence is a reason to walk away — a single line extension missing its Natural Product Number because an application is genuinely close to being issued is a very different finding than a flagship product that has been selling without one for years, and the two call for different responses. A finding you can point to specifically, with a clear description of what it is and what it would cost or how long it would take to fix, is something you can actually negotiate around — through a price adjustment, a holdback, or a condition that the gap is closed before closing — in a way that a vague sense that something felt off about the licensing file never lets you do.

Findings that most often kill this kind of deal

• A product is confirmed to be selling without a valid Natural Product Number, exposing the buyer to a compliance action after closing
• Health Canada signals it will decline or significantly delay reissuing the licences to the buyer’s name
• The contract manufacturer’s site licence turns out to be suspended or under review, or the manufacturer will not commit to continuing after the sale
• A meaningful share of inventory is at or past its labelled expiry date, materially overstating the reported inventory value